BC Guidelines are clinical practice guidelines and protocols that provide recommendations to B.C. practitioners on delivering high quality, appropriate care to patients with specific clinical conditions or diseases. These “Made in BC” clinical practice guidelines are developed by the Guidelines and Protocol Advisory Committee (GPAC), an advisory committee to the Medical Services Commission. The primary audience for BC Guidelines is BC physicians, nurse practitioners, and medical students. However, other audiences such as health educators, health authorities, allied health organizations, pharmacists, and nurses may also find them to be a useful resource.
There are several ways to find the guidelines you are looking for.
- Browse the guidelines alphabetically or by topic area.
- You can also download the entire collection of BC Guidelines (ZIP, 43MB) for future reference.
New Partner Guideline: A Guideline for the Clinical Management of Opioid Use Disorder
The British Columbia Centre on Substance Use and the Ministry of Health have released A Guideline for the Clinical Management of Opioid Use Disorder. The guideline provides evidence-based recommendations to BC physicians and nurse practitioners for the clinical management of opioid use disorder.
- Recommending buprenorphine/naloxone as the preferred first-line option for treatment of opioid use disorder; and
- Strongly recommending against offering withdrawal management (also known as 'detox') as a stand-alone treatment, unless a plan is in place to transition individuals to continued addiction treatment following completion of withdrawal management.
Until June 5, 2017, this guideline is provided for educational purposes. For clinicians wishing to prescribe buprenorphine/naloxone and/or methadone please refer to the College of Physicians and Surgeons of BC’s Methadone and Buprenorphine: Clinical Practice Guideline for Opioid Use Disorder. After June 5, 2017, this guideline will become the guideline for the province of British Columbia.
For more information on the BC Centre on Substance Use, check out the website at: www.bccsu.ca
Introducing the New Online External Review Page
BC Guidelines is pleased to introduce a new External Review of Guidelines page to our website. This new page allows peer reviewers to download draft guidelines and submit questionnaire feedback directly from our website. We are also happy to provide a new online questionnaire that can be submitted through your web browser. Participating as an external reviewer has never been easier!
Recently Published BC Guidelines
- Special Endocrine Testing (2016)
- Diabetes Care (2015)
- Asthma in Adults - Recognition, Diagnosis and Management (2015)
- Asthma in Children - Diagnosis and Management (2015)
- Chronic Heart Failure - Diagnosis and Management (2015)
- Atrial Fibrillation – Diagnosis and Management (2015)
- Use of Non-Vitamin K Antagonist Oral Anticoagulants (NOAC) in Non-Valvular Atrial Fibrillation (2015)
- Stroke and Transient Ischemic Attack – Acute and Long-Term Management (2015)
- Warfarin Therapy - Management During Invasive Procedures and Surgery (2015)
- Warfarin Therapy Management (2015)
Updates to BC Guidelines - As of August 2016
- Colorectal Screening for Cancer Prevention in Asymptomatic Patients (2013) – Revised 2016
Updated the time interval for fecal immunochemical test (FIT) from every 1-2 years for average-risk individuals aged 50 – 74 years to every 2 years. This recommendation now aligns with BC Cancer Agency’s screening recommendations. For more information, visit BC Cancer Agency’s screening program website.
- Genital Tract Cancers in Females: Human Papillomavirus Related Cancers (Cervical, Vaginal & Vulvar) (2014) – Revised 2016
Updates to the cervical cancer screening recommendations to align with the changes to the BC Cancer Agency’s screening program in June 2016. For more information about the screening program changes, refer to the BC Cancer Agency’s Policy Change Reference Guide.
- Hypertension - Diagnosis and Management (2015) – Revised 2016
Updates to the Medication Table due to the PharmaCare’s Reference Drug Program being modernized. Click below for Decision Trees for Switching Drugs to assist health professionals:
- Cognitive Impairment: Recognition, Diagnosis and Management in Primary Care (2014) – Revised 2016
Updates to Medication Table and includes the outcomes from the Alzheimer’s Drug Therapy Initiative. For more information about the changes to PharmaCare coverage for cholinesterase inhibitors, refer to the Information Sheet on the PharmaCare website.
Other Important News
Earn Continuing Medical Education Credits with BC Guidelines
With the launch of the College of Family Physicians of Canada's new Mainpro+ system, there are now more opportunities to earn credit for continuing medical education / continuing professional development through using and participating in the development of BC Guidelines. For more details, see Continuing Professional Development (CPD) Credits.